Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis's Voltaren Gel has received US regulatory approval as the first topical prescription treatment for pain associated with osteoarthritis in joints amenable to topical treatment, such as the knees and those of the hands.
Subscribe to our email newsletter
Clinical trials have demonstrated Voltaren Gel to be highly effective in treating osteoarthritis pain in the hands and knees, which are the body’s most commonly affected joints, according to Novartis. The Swiss pharmaceutical company said that Voltaren Gel delivers effective pain relief with a favorable safety profile as its systemic absorption is 94% less than the comparable oral diclofenac treatment.
Jorge Insuasty, senior vice president of R&D at Novartis Consumer Health, said: “Voltaren Gel represents an important clinical milestone – it is the first prescription topical treatment in the US shown to relieve osteoarthritis pain and to clinically prove efficacy in treating both the knees and hands. Patients now have the option to effectively treat osteoarthritis pain directly at the source with favorable tolerability.”